Cross Keys Capital Advises Retina Associates of Utah, P.C., on Its Partnership with Retina Consultants of America
November 04, 2021 16:02 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, FL, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Cross Keys Capital, a leading investment bank to physician group practices and healthcare service and technology companies, is pleased to...
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
November 01, 2021 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Newly Formed Lanier Biotherapeutics Enters into License Agreement with Alloy Therapeutics
October 05, 2021 08:00 ET
|
Lanier Biotherapeutics
BOGART, Ga., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Lanier Biotherapeutics Inc., (“Lanier” or the “Company”), a developer of first-in-class antibodies targeting retina, dermatology, and Type 2...
Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference
September 30, 2021 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Worldwide Choroidal Neovascularization Industry to 2026 - Featuring Novartis, Pfizer and Regeneron Pharmaceuticals Among Others
September 30, 2021 06:53 ET
|
Research and Markets
Dublin, Sept. 30, 2021 (GLOBE NEWSWIRE) -- The "Choroidal Neovascularization Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD
September 28, 2021 07:30 ET
|
Graybug Vision, Inc.
55% of GB-102 1mg patients in Extension Study experienced duration of 12+ months, while maintaining their visual acuity and central retinal thickness73% reduction of injection burden for patients...
Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference
September 21, 2021 17:15 ET
|
Graybug Vision, Inc.
BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Cross Keys Capital Advises Rockland Retina on Its Sale to Retina Consultants of America
September 21, 2021 09:00 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Cross Keys Capital served as the exclusive sell-side M&A advisor to Rockland Retina (RR) in its partnership with Retina Consultants of America...
Worldwide Diabetic Retinopathy Industry to 2026 - by Type, Treatment Type, End-user and Region
August 16, 2021 08:38 ET
|
Research and Markets
Dublin, Aug. 16, 2021 (GLOBE NEWSWIRE) -- The "Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Developments
August 11, 2021 16:05 ET
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...